Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2025-02-18 DOI:10.1016/j.ejmech.2025.117402
Gianluigi Lauro, Michela Aliberti, Mauro De Nisco, Silvana Pedatella, Giacomo Pepe, Manuela Giovanna Basilicata, Maria Giovanna Chini, Katrin Fischer, Robert K. Hofstetter, Oliver Werz, Maria Grazia Ferraro, Marialuisa Piccolo, Carlo Irace, Anella Saviano, Pietro Campiglia, Alessia Bertamino, Carmine Ostacolo, Tania Ciaglia, Michele Manfra, Giuseppe Bifulco
{"title":"Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition","authors":"Gianluigi Lauro, Michela Aliberti, Mauro De Nisco, Silvana Pedatella, Giacomo Pepe, Manuela Giovanna Basilicata, Maria Giovanna Chini, Katrin Fischer, Robert K. Hofstetter, Oliver Werz, Maria Grazia Ferraro, Marialuisa Piccolo, Carlo Irace, Anella Saviano, Pietro Campiglia, Alessia Bertamino, Carmine Ostacolo, Tania Ciaglia, Michele Manfra, Giuseppe Bifulco","doi":"10.1016/j.ejmech.2025.117402","DOIUrl":null,"url":null,"abstract":"We report the identification of a new set of compounds based on the furazanopyrazine core interfering with eicosanoid biosynthesis and acting as potentially effective anti-inflammatory and anticancer agents. Based on our previous promising results on a set of furazanopyrazine-based compounds against the microsomal prostaglandin E<sub>2</sub> synthase-1 (mPGES-1) enzyme, we here identified derivatives with improved pharmacokinetic properties by replacing the ester moiety with a more stable ether group.A focused virtual library of 1 × 10<sup>4</sup> molecules was built and screened against mPGES-1 through molecular docking experiments, leading to the selection of 10 candidates for synthesis and biological evaluation. Several molecules were found to inhibit mPGES-1 with IC<sub>50</sub> values in the low micromolar range. Additional computational studies on the collection of synthesized compounds demonstrated that compound <strong>3b</strong>, previously emerged as an mPGES-1 inhibitor, interfered with soluble epoxide hydrolase (sEH) activity, thus emerging as a valuable dual mPGES-1/sEH inhibitor. The pharmacokinetic features of the most potent compounds were accurately estimated. Unfortunately, poor outcomes were obtained for <strong>3b</strong>; on the other hand, compound <strong>7e</strong> exhibited promising mPGES-1 inhibition and excellent pharmacokinetic profile, demonstrating that the novel furazanopyrazine-based items with ether functionalities possess improved pharmacokinetic properties compared to the ester-based compounds reported in our previous study. Additionally, the anticancer properties of <strong>7e</strong> and <strong>7d</strong>, the latter emerged as the most active mPGES-1 inhibitor, were evaluated and both compounds showed promising activities against HCT-116 human colorectal cancer (CRC) cells.These findings highlight the furazanopyrazine core as a promising scaffold for disclosing new anti-inflammatory drugs with the ability to inhibit targets belonging to arachidonic acid cascade.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"13 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.117402","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

We report the identification of a new set of compounds based on the furazanopyrazine core interfering with eicosanoid biosynthesis and acting as potentially effective anti-inflammatory and anticancer agents. Based on our previous promising results on a set of furazanopyrazine-based compounds against the microsomal prostaglandin E2 synthase-1 (mPGES-1) enzyme, we here identified derivatives with improved pharmacokinetic properties by replacing the ester moiety with a more stable ether group.A focused virtual library of 1 × 104 molecules was built and screened against mPGES-1 through molecular docking experiments, leading to the selection of 10 candidates for synthesis and biological evaluation. Several molecules were found to inhibit mPGES-1 with IC50 values in the low micromolar range. Additional computational studies on the collection of synthesized compounds demonstrated that compound 3b, previously emerged as an mPGES-1 inhibitor, interfered with soluble epoxide hydrolase (sEH) activity, thus emerging as a valuable dual mPGES-1/sEH inhibitor. The pharmacokinetic features of the most potent compounds were accurately estimated. Unfortunately, poor outcomes were obtained for 3b; on the other hand, compound 7e exhibited promising mPGES-1 inhibition and excellent pharmacokinetic profile, demonstrating that the novel furazanopyrazine-based items with ether functionalities possess improved pharmacokinetic properties compared to the ester-based compounds reported in our previous study. Additionally, the anticancer properties of 7e and 7d, the latter emerged as the most active mPGES-1 inhibitor, were evaluated and both compounds showed promising activities against HCT-116 human colorectal cancer (CRC) cells.These findings highlight the furazanopyrazine core as a promising scaffold for disclosing new anti-inflammatory drugs with the ability to inhibit targets belonging to arachidonic acid cascade.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
我们报告了一组基于呋喃并吡嗪核心的新化合物的鉴定结果,这些化合物可干扰二十碳烷类化合物的生物合成,并可作为潜在有效的抗炎药和抗癌药。基于我们之前针对微粒体前列腺素 E2 合酶-1(mPGES-1)的一组呋喃并吡嗪类化合物所取得的令人鼓舞的成果,我们在这里通过用更稳定的醚基取代酯基,鉴定出具有更好药代动力学特性的衍生物。研究发现,一些分子对 mPGES-1 具有抑制作用,其 IC50 值在低微摩尔范围内。对合成的化合物集进行的其他计算研究表明,之前作为 mPGES-1 抑制剂出现的化合物 3b 干扰了可溶性环氧化物水解酶(sEH)的活性,因此成为一种有价值的 mPGES-1/sEH 双重抑制剂。我们准确地估算了药效最强的化合物的药代动力学特征。遗憾的是,3b 的药代动力学结果不佳;而化合物 7e 则表现出了良好的 mPGES-1 抑制作用和药代动力学特征,这表明与我们之前研究中报道的酯基化合物相比,新型呋喃并吡嗪类醚官能团化合物具有更好的药代动力学特性。此外,我们还评估了 7e 和 7d(后者是活性最强的 mPGES-1 抑制剂)的抗癌特性,这两种化合物对 HCT-116 人结肠直肠癌(CRC)细胞都显示出良好的活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Editorial Board Contents continued Graphical abstract TOC Graphical abstract TOC In silico modeling of targeted protein degradation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1